Comparative In Vitro Activities of GSK2251052, a Novel Boron-Containing Leucyl-tRNA Synthetase Inhibitor, against 916 Anaerobic Organisms | Zendy

Ellie J. C. Goldstein | Zendy; Diane M. Citron | Zendy; Kerin L. Tyrrell | Zendy; C. Vreni Merriam | Zendy

Open Access

Comparative In Vitro Activities of GSK2251052, a Novel Boron-Containing Leucyl-tRNA Synthetase Inhibitor, against 916 Anaerobic Organisms

Author(s) -

Ellie J. C. Goldstein,

Diane M. Citron,

Kerin L. Tyrrell,

C. Vreni Merriam

Publication year - 2013

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02580-12

Subject(s) - bacteroides thetaiotaomicron , bacteroides fragilis , clostridium perfringens , microbiology and biotechnology , in vitro , bacteroides , biology , antibiotics , bacteria , biochemistry , genetics

We studied the comparativein vitro activity of GSK2251052, a novel boron leucyl-tRNA synthetase inhibitor, against 916 clinical anaerobic isolates using CLSI methods. The GSK MIC50 /MIC90 for all isolates tested were 2 and 4 μg/ml, and the MIC90 s against 302Bacteroides fragilis andBacteroides thetaiotaomicron strains were 4 and 8 μg/ml, respectively. AllClostridium perfringens strains had GSK2251052 MICs of >32 μg/ml. There was no relationship between increased MICs for any other antibiotics and that of GSK2251052.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research